A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Thomas, Markus ^a   Kienast, Yvonne ^a   Scheuer, Werner ^a   Bähner, Monika ^a   Kaluza, Klaus ^a   Gassner, Christian ^a   Herting, Frank ^a   Brinkmann, Ulrich ^a   Seeber, Stefan ^a   Kavlie, Anita ^b   Welschof, Martin ^b,c   Ries, Stefan ^a   Weidner, K Michael ^a   Regula, Jörg T ^a   Klein, Christian ^a,d  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b Affitech AS   (Norway)

^c Opsona Therapeutics Ltd   (Ireland)

^d Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; LC06 ANTIBODY; LC08 ANTIBODY; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; CORNEA TUMOR; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; CORNEA; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; IMMUNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RANDOMIZATION; SCID MOUSE; TUMOR CELL LINE; VASCULARIZATION;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CORNEA; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RANDOM ALLOCATION; RECEPTOR, TIE-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873545836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054923     Document Type: Article

References (55)

1. Kesisis G, Broxterman H, Giaccone G, (2007) Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 13: 2795-2809.
2. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161-1169.
3. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60.
4. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, et al. (2003) Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 1721-1727.
5. Augustin HG, Koh GY, Thurston G, Alitalo K, (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177.
6. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, et al. (2004) The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156.
7. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, et al. (2006) Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci U S A 103: 15491-15496.
8. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, et al. (2000) Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19: 4549-4552.
9. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, et al. (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49: 659-670.
10. Joussen AM, (2001) Vascular plasticity-the role of the angiopoietins in modulating ocular angiogenesis. Graefes Arch Clin Exp Ophthalmol 239: 972-975.
11. Ahmad SA, Liu W, Jung YD, Fan F, Reinmuth N, et al. (2001) Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92: 1138-1143.
12. Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergun S, (2000) The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res 20: 5217-5220.
13. Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, et al. (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159: 391-400.
14. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, et al. (2010) A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156.
15. Huang H, Lai JY, Do J, Liu D, Li L, et al. (2011) Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth. Clin Cancer Res.
16. Burger RA, (2012) Advances in ovarian cancer disease control. Gynecol Oncol 124: 5-9.
17. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, et al. (2010) Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16: 3044-3056.
18. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, et al. (2012) MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40: 1321-1330.
19. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, et al. (2009) Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27: 3557-3565.
20. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, et al. (1999) Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 79: 707-717.
21. Schneider T, Osl F, Friess T, Stockinger H, Scheuer WV, (2002) Quantification of human Alu sequences by real-time PCR-an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis 19: 571-582.
22. Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, et al. (2011) A human neutralizing antibody specific to ang-2 inhibits ocular angiogenesis. Microcirculation 18: 598-607.
23. Stratmann A, Risau W, Plate KH, (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153: 1459-1466.
24. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, et al. (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63: 3403-3412.
25. Oliner J, Min H, Leal J, Yu D, Rao S, et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6: 507-516.
26. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, et al. (2008) Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27: 522-534.
27. Lobov IB, Brooks PC, Lang RA, (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99: 11205-11210.
28. Thurston G, Suri C, Smith K, McClain J, Sato TN, et al. (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514.
29. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, et al. (2009) Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170.
30. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, et al. (2009) Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333.
31. Pfaff D, Fiedler U, Augustin HG, (2006) Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol 80: 719-726.
32. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180.
33. Benjamin LE, Hemo I, Keshet E, (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598.
34. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, et al. (2006) Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66: 3639-3648.
35. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, et al. (2011) Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526.
36. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, et al. (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21: 66-81.
37. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
38. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
39. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998.
40. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, et al. (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30: 362-371.
41. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, et al. (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double-blind, placebo-controlled, phase 2 study. Cancer.
42. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, et al. (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81: 567-574.
43. Mochizuki Y, Nakamura T, Kanetake H, Kanda S, (2002) Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 115: 175-183.
44. Pietila R, Natynki M, Tammela T, Kangas J, Pulkki KH, et al. (2012) Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses. J Cell Sci 125: 2212-2223.
45. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, et al. (2008) Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10: 527-537.
46. Hatfield KJ, Hatfield KJ, Hovland R, Hovland R, Oyan AM, et al. (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22: 287-293.
47. Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, et al. (2008) Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res 146: 16-23.
48. Coxon A, Bready J, Min H, Kaufman S, Leal J, et al. (2010) Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 9: 2641-2651.
49. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, et al. (2009) Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15: 1384-1392.
50. Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, et al. (2007) Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res 67: 4254-4263.
51. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, et al. (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132: 200-206.
52. Hu B, Guo P, Fang Q, Tao HQ, Wang D, et al. (2003) Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 100: 8904-8909.
53. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, et al. (2006) Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 98: 261-266.
54. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, et al. (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63: 3370-3377.
55. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, et al. (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108: 11187-11192.